Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide Acetate in Diabetic Retinopathy
NCT00131144Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 1999
- Primary completion
- Dec 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of octreotide in diabetic retinopathy (DR) (3 arms), sponsored by Novartis. Primary endpoint: Time to progression of diabetic retinopathy. Started Nov 1999; status: completed.
02
Drugs
octreotide
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT00131144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131144.